Free Trial
OTCMKTS:ABCZY

Abcam (ABCZY) Stock Price, News & Analysis

Abcam logo

About Abcam Stock (OTCMKTS:ABCZY)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
5,400 shs
Average Volume
4,712 shs
Market Capitalization
$3.98 billion
P/E Ratio
N/A
Dividend Yield
0.36%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Receive ABCZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

ABCZY Stock News Headlines

Abcam appoints Markus Lusser as new President
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Abcam shareholders approve $5.7 billion Danaher deal
Abcam founder ends fight to block takeover
See More Headlines

ABCZY Stock Analysis - Frequently Asked Questions

Abcam subsidiaries include Abcam Trading (Shanghai) Co. Ltd., Abcam US Group Holdings Inc., Abcam (US) Ltd., and Epitomics Inc.

Shares of ABCZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Industrial Inorganic Chemicals
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ABCZY
Previous Symbol
NASDAQ:ABCZY
CIK
N/A
Fax
N/A
Employees
1,750
Year Founded
1998

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$336.37 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.98 billion
Optionable
Not Optionable
Beta
1.29

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (OTCMKTS:ABCZY) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners